Daylight Photodynamic Therapy for Actinic Keratosis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 1, 2018

Study Completion Date

July 1, 2019

Conditions
Actinic Keratoses
Interventions
DRUG

Aminolevulinic Acid Topical 20% Topical Solution

PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).

DEVICE

BLU-U blue light phototherapy illuminator

Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.

Trial Locations (1)

94115

UCSF Dermatology, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03322293 - Daylight Photodynamic Therapy for Actinic Keratosis | Biotech Hunter | Biotech Hunter